Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,852 papers from all fields of science
Search
Sign In
Create Free Account
Optune
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
QOLP-24. PATIENTS’/PARENTS’ EXPERIENCES OF RECEIVING OPTUNE DELIVERED TUMOR TREATMENT FIELDS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048
Jin-Shei Lai
,
S. Goldman
,
+6 authors
I. Dunkel
Neuro-Oncology
2019
Corpus ID: 209236289
Optune-delivered TTFields is a promising anti-mitotic FDA-approved cancer therapy in adult patients with high-grade gliomas…
Expand
2019
2019
NIMG-41. RAPID AND ACCURATE CREATION OF PATIENT-SPECIFIC COMPUTATIONAL MODELS FOR GBM PATIENTS RECEIVING OPTUNE THERAPY WITH CONVENTIONAL IMAGING (T1w/PD)
C. Wenger
,
Hadas Sara Hershkovich
,
C. Tempel-Brami
,
M. Giladi
,
Z. Bomzon
Neuro-Oncology
2019
Corpus ID: 209290181
For understanding the electric field distributions in glioblastoma (GBM) patients receiving OptuneTM therapy computational…
Expand
2017
2017
Long-term daily temozolomide with dose-dependent efficacy in MGMT promotor methylation negative recurrent high-grade astrocytoma
Zhengqiu Zhou
,
Tracy A. Howard
,
J. Villano
Cancer Chemotherapy and Pharmacology
2017
Corpus ID: 25537443
Temozolomide (TMZ) for malignant gliomas is traditionally dosed in 5 out of a 28-day cycle, however alternative regimens exist…
Expand
Review
2016
Review
2016
ACTR-41. A PHASE II, SINGLE ARM STUDY OF OPTUNE® IN BEVACIZUMAB-NAIVE SUBJECTS WITH RECURRENT WHO GRADE III MALIGNANT GLIOMA
Daniel O’Connell
,
J. Carrillo
,
X. Kong
,
B. Fu
,
D. Bota
2016
Corpus ID: 79326738
There is an unmet clinical need for the treatment of progressive or recurrent anaplastic glioma (World Health Organization [WHO…
Expand
2015
2015
Technological Advances in the Treatment of Cancer: Combining Modalities to Optimize Outcomes.
E. Wong
,
S. Toms
,
M. Ahluwalia
Clinical advances in hematology & oncology : H&O
2015
Corpus ID: 40089746
The anticancer treatment modality tumor treating fields (TTFields; Optune, Novocure) use the lower frequency range of the…
Expand
2015
2015
Younger Age but Not Receptor Status May Predispose to Radiation Necrosis in Radiation Therapy for Breast Cancer Brain Metastasis
R. Levin-Epstein
,
Jason Wang
,
+8 authors
T. Kaprealian
2015
Corpus ID: 74301803
2015
2015
NovoTTF-100A system (tumor treating fields) transducer array layout planning for glioblastoma: Results of a NovoTAL system user study.
A. Chaudhry
,
L. Benson
,
+4 authors
Y. Palti
2015
Corpus ID: 79149964
e13029 Background: The NovoTTF-100A System (Optune) generates Tumor Treating Fields (TTFields), an effective anti-mitotic therapy…
Expand
Review
2015
Review
2015
Electrical device for patients with glioblastoma met with support, skepticism: Some question the device's efficacy, others tout it as a new standard of care
C. Printz
Cancer
2015
Corpus ID: 34235850
969 R leading a study of an electrical device that treats glioblastomas tout it as a new standard of care for the disease…
Expand
2008
2008
Broad tuning range filtering system with Optune interferometers
N. Miron
Organic Photonics + Electronics
2008
Corpus ID: 98049334
An optical system built with two Optune interferometers cascaded according to Vernier principle has attractive tunable band pass…
Expand
2007
2007
A novel optical tuning technology
N. Miron
SPIE OPTO
2007
Corpus ID: 109782602
A novel optical tuning technology based on new non-resonant interferometer (Optune interferometer) is described. This…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required